What Is KLOW?

Published August 2026 · Patriot Labs Research Team · ~11 min read

What KLOW actually is

KLOW is not a molecule. It is a packaging decision — four separately synthesised peptides weighed out, combined, and lyophilised into one vial so that a single reconstitution produces a solution containing all four.

The name is a vendor acronym rather than a chemical designation. It is conventionally read as KPV bolted onto the three peptides that make up the Glow blend — GHK-Cu, TB-500 and BPC-157. That reading is consistent with how the catalog describes it: a "KPV / GHK-Cu / TB-500 / BPC-157 cocktail studied for systemic regeneration research models."

Two consequences follow from "it is a packaging decision," and both matter more than they sound. First, nothing about the blend is standardised. There is no monograph, no pharmacopoeial entry and no agreed ratio — two vials labelled KLOW from two suppliers can contain meaningfully different mass splits. Second, every published claim attached to KLOW is really a claim about one of its four components, studied on its own. We go through that distinction in more detail in why peptides are blended.

Reading the label: 80 mg as 10/10/10/50

The Patriot Labs listing gives the vial as 80 mg total, expressed as 10/10/10/50. That string is a mass split, not a use instruction — it states how the 80 mg of dry powder in the vial is divided between the four peptides.

The arithmetic is internally consistent — 10 + 10 + 10 + 50 = 80 mg, so the split accounts for the stated total with nothing unassigned. The per-component assignment follows the order in which the catalog names the components, which is the natural reading of a positional dose string:

A caveat worth stating rather than glossing: a positional string like 10/10/10/50 is only unambiguous if the reader maps it to the component list in the same order the vendor wrote it. Three of the four figures are identical, so the only assignment that could be misread is which component carries the 50 mg. Present the split as the catalog states it, and confirm the per-component masses against the certificate of analysis for the specific lot rather than against any guide, this one included — see understanding peptide COA testing for what a useful COA on a multi-component vial should show.

The distribution itself is informative. BPC-157 carries nearly two-thirds of the mass; the other three split the remainder evenly. On a molar basis the imbalance is different again, because these peptides differ substantially in molecular weight — KPV is three residues, BPC-157 is fifteen — so equal milligram figures do not mean equal numbers of molecules. A 10 mg portion of a tripeptide contains far more molecules than a 10 mg portion of a pentadecapeptide.

KPV: the fourth component, in depth

KPV is the component that turns Glow into KLOW, and it is the one most people know least about, so it gets the most space here.

Chemically it is about as simple as a peptide gets: three amino acids — lysine–proline–valine — joined in that order. It is the C-terminal tripeptide of α-melanocyte-stimulating hormone (α-MSH), occupying residues 11–13 of the thirteen-residue sequence SYSMEHFRWGKPV. In the literature it is often written α-MSH(11–13).

α-MSH is a melanocortin. Its best-known role is pigmentation, but it is also a broadly anti-inflammatory signalling molecule: a 2021 review in Pharmaceuticals summarises α-MSH as suppressing NF-κB activity through cAMP-dependent pathways and reducing pro-inflammatory mediators including TNF-α, IL-1, IL-6 and IL-8 while inducing IL-10.

The interesting part is what happens when the hormone is stripped down to its last three residues. Reviews of the melanocortin peptide family report that the C-terminal fragment "retains almost all of the anti-inflammatory capacity of the full hormone" while showing "a lack of any pigmentory action" — the anti-inflammatory signalling and the pigment signalling separate. That is the whole reason a three-residue fragment gets studied at all instead of the parent hormone.

Mechanistically, KPV is unusual in a way researchers have not fully resolved. It appears to act without binding the melanocortin receptors (MC1R–MC5R) that mediate α-MSH's classical effects. The same review chapter states plainly that "the exact signaling mechanism utilized by KPV and related peptides currently is unknown," while noting substantial overlap between KPV's anti-inflammatory signalling and α-MSH's. A murine colitis study reinforced the receptor-independence point from the other direction: KPV remained protective in melanocortin-1-receptor-deficient mice.

The best-characterised route into cells is not a receptor at all. Work published in Gastroenterology in 2008 identified PepT1 — the di- and tripeptide transporter expressed on intestinal epithelium and, under inflammatory conditions, on immune cells — as the carrier that moves KPV into the cytoplasm. Radiolabelled uptake studies confirmed the transport; the anti-inflammatory effect tracked with PepT1 expression. That is a tidy piece of mechanism: a transporter evolved to absorb dietary peptide fragments also happens to import a signalling tripeptide.

What the KPV literature actually shows

KPV's evidence base is concentrated in gut inflammation, and it is almost entirely preclinical.

In the 2008 Gastroenterology work, human intestinal epithelial cell lines and T cells were challenged with pro-inflammatory cytokines. KPV at nanomolar concentrations (on the order of 10⁻⁹ M) suppressed NF-κB and MAP kinase signalling and reduced pro-inflammatory cytokine secretion in culture. Two chemically induced murine colitis models showed reduced disease severity and lower pro-inflammatory gene expression after oral administration.

An independent group reported convergent results the same year in Inflammatory Bowel Diseases, using DSS-induced colitis and CD45RB^hi transfer colitis in mice. KPV-treated animals showed earlier recovery and stronger body-weight regain, with reduced histological inflammatory infiltrate and reduced colonic myeloperoxidase activity — a standard proxy for neutrophil infiltration. Effects were also observed in the transfer-colitis model, which is immune-driven rather than chemically driven, and in melanocortin-1-receptor-deficient animals.

A 2017 Molecular Therapy paper approached the same problem from a delivery angle, loading KPV into hyaluronic-acid-functionalised nanoparticles roughly 272 nm across and delivering them orally in a chitosan–alginate hydrogel to target colonic epithelium and macrophages in a murine colitis model. The functionalised particles outperformed uncoated ones on mucosal damage and TNF-α expression. Note what that study implies: the researchers built an elaborate delivery vehicle because getting a free tripeptide to a specific tissue is difficult.

Outside the gut, coverage thins quickly. A 2000 study in the Journal of Leukocyte Biology reported that both full-length α-MSH and the KPV fragment inhibited Staphylococcus aureus colony formation and reduced Candida albicans viability and germ-tube formation in vitro, across a broad concentration range, with the effect linked to cAMP elevation. In skin and wound contexts, a 2025 review of tripeptides in wound healing describes KPV-loaded hydrogels reducing IL-1β and TNF-α while upregulating IL-10 in experimental systems — and, in the same breath, flags that KPV research remains largely in vitro or ex vivo with insufficient evaluation in standard animal wound-healing models.

That is the honest summary: a coherent, replicated anti-inflammatory signal in rodent colitis, a plausible transporter-based mechanism, scattered in-vitro antimicrobial and wound-model findings, and essentially nothing in humans.

The other three, in brief

Each of the remaining components has a full guide on this site, so the treatment here is deliberately short.

GHK-Cu is a copper-binding tripeptide (glycyl-L-histidyl-L-lysine complexed with Cu²⁺). The 2025 International Journal of Medical Sciences tripeptide review describes it as stimulating fibroblast migration, enhancing collagen deposition and supporting angiogenesis in experimental systems. It is the component that carries the copper, which has handling implications discussed below.

TB-500 is a synthetic fragment corresponding to the actin-binding region of thymosin β4. A 2026 scoping review in Applied Sciences mapped 80 studies across the thymosin β4 / TB-500 literature and found it heavily weighted toward in-vitro and mixed designs, with roughly 87.5% of studies examining thymosin β4 itself rather than TB-500, and direct musculoskeletal tissues accounting for around 14% of studies. The authors identified no human interventional trials for tendon or ligament repair.

BPC-157 is a fifteen-residue sequence derived from a protein found in gastric juice. A 2021 Frontiers in Pharmacology review catalogues wound-healing effects across skin, fistula, muscle, tendon, ligament, bone and vascular models, mostly in rats and mice with some rabbit and small-pig work. A 2025 systematic review in HSS Journal screened the orthopaedic literature and found 36 studies, 35 of them preclinical and one clinical — a retrospective series of 12 patients. That ratio is the single most useful number for calibrating expectations. The BPC-157 and TB-500 literatures are set against each other directly in that comparison guide.

KLOW vs Glow

The cleanest way to understand KLOW is as a modification of Glow: same repair-associated trio, plus KPV, with the mass split rearranged.

We deliberately do not restate Glow's per-component masses here. Those figures belong to that product's listing and should be read there rather than inferred from this page. What the table is for is the structural difference: KLOW is a wider blend with a distinct fourth mechanism, and Glow is the narrower three-component version.

Why these four were grouped

Blends are assembled on a mechanistic argument, and it is worth stating the argument explicitly so it can be judged rather than absorbed.

The argument runs like this. Three of the four components are studied in the context of tissue repair and sit at different points of the same broad process: GHK-Cu in matrix and fibroblast biology, TB-500 in actin dynamics and cell migration, BPC-157 in angiogenesis and growth-factor signalling. The fourth, KPV, is not a repair peptide at all — it is studied for damping the inflammatory signalling that accompanies injury, principally through NF-κB and MAP kinase suppression. Adding it turns a repair stack into a repair-plus-inflammation-signalling stack.

That is a reasonable-sounding hypothesis. It is also, at present, only a hypothesis. Nobody has published a study of the four together. Grouping peptides whose individual mechanisms look complementary on a diagram is not the same as demonstrating that the combination behaves as the diagram predicts — that would require the combination itself to be tested against each component alone, which has not been done. Combining also removes the ability to attribute an observation to any single component, which is a real cost in a research setting; the general trade-off is covered in why peptides are blended. Where a protocol needs the tripeptide isolated, KPV is stocked as a single-component vial.

Bench considerations for a four-component vial

A multi-component lyophilisate raises handling questions a single peptide does not.

One solvent, four solutes. Reconstitution introduces a single diluent to four peptides with different solubility and stability profiles. The blend is fixed at the point of manufacture, so the components cannot be handled separately once the vial is sealed. General technique is covered in how to reconstitute research peptides.

Copper chemistry. GHK-Cu is a metal complex rather than a bare peptide, and copper is redox-active. Metal-catalysed oxidation is a recognised degradation route for peptides in solution, which makes light, temperature and time control more consequential for a copper-containing blend than for a simple sequence. See how to store research peptides.

Analytical verification is harder. Confirming identity and purity in a four-peptide mixture requires a method that resolves all four, and a tripeptide and a pentadecapeptide behave very differently on a chromatographic column. A single-peak purity figure means nothing on a blend. Ask what the assay actually resolved.

Short half-lives in the literature. The 2025 tripeptide review notes plasma half-lives for tripeptides on the order of minutes and poor skin permeation owing to hydrophilicity; the HSS Journal BPC-157 review reports a sub-30-minute half-life with hepatic processing and renal clearance. Anything designed around these peptides has to account for how quickly they disappear in the models where they have been measured.

What the evidence does not establish

This is the section that matters most, and it is longer than the positive findings for a reason.

The four-way combination is entirely unstudied. There is no published study — in cells, in animals or otherwise — of KPV, GHK-Cu, TB-500 and BPC-157 administered together. Nothing is known about whether they interfere with one another chemically in a shared vial, whether their effects are additive, redundant or antagonistic in any model, or whether the specific 10/10/10/50 split is better or worse than any other. Every finding cited on this page comes from a study of one component alone. Treating the blend's evidence base as the sum of four separate literatures is a logical shortcut, not a demonstrated fact.

KPV's evidence base is largely animal-model and in-vitro. The strongest KPV results come from chemically induced and transfer colitis in mice and from cultured intestinal epithelial and immune cell lines. Chemically induced colitis is a useful inflammation model but it is not human inflammatory bowel disease; it is acute, chemically driven and reversible in ways the human condition is not. Outside the gut, the 2025 tripeptide review states directly that KPV work remains largely in vitro or ex vivo with insufficient evaluation in standard animal wound-healing models. We found no human interventional trial data for KPV in the sources retrieved for this guide.

KPV's mechanism is incompletely characterised. KPV appears to act independently of the melanocortin receptors that mediate α-MSH's classical effects, and the reviews say outright that the signalling pathway it does use is unknown. PepT1-mediated uptake is well supported for intestinal and immune cells, but that transporter's tissue distribution constrains where the mechanism can plausibly apply. Extrapolating gut findings to other tissues is not supported by the transport data.

The repair components are thinner than they appear. The TB-500 scoping review found the literature dominated by thymosin β4 rather than TB-500 itself — direct TB-500 research amounted to a single study in that mapping — and identified no human interventional trials for musculoskeletal repair. The authors noted explicitly that the published literature "does not match the way these peptides are often discussed in clinical, performance, or public-facing settings." For BPC-157, the orthopaedic systematic review found one clinical study among 36, a retrospective series of 12 patients, and stated that no human safety data are available.

Preclinical model limitations compound. Rodent colitis and rodent tendon injury are short-duration, deliberately induced, genetically homogeneous systems. Group sizes in this literature are typically small. Positive findings frequently come from a single laboratory, and independent replication in the KPV literature is limited to the two 2008 colitis papers converging on a similar conclusion. Publication bias toward positive results is a live concern in any small preclinical field.

Purity and composition claims require lot-specific verification. Because blends are manufactured products with no standard, the only evidence that a given vial contains what the label says is that vial's certificate of analysis. Nothing in the published literature speaks to the contents of any particular product.

None of this makes KLOW uninteresting as a research material. It makes it a research material — four peptides with real but preclinical individual literatures, combined on an untested rationale.

Frequently asked questions

What does the name KLOW stand for? It is a vendor-coined acronym built from its components, conventionally read as KPV added to the three peptides of the Glow blend. It is not a chemical name or a standardised formulation, and the same four letters can denote different ratios at different suppliers.

What is KPV, exactly? A tripeptide of lysine, proline and valine, corresponding to residues 11–13 of α-melanocyte-stimulating hormone. It is studied for anti-inflammatory signalling — suppression of NF-κB and MAP kinase activity in cultured cells — and has been examined in rodent colitis models.

Does the 10/10/10/50 split add up? Yes. The four figures total 80 mg, matching the stated vial content, with nothing unassigned. The per-component mapping follows the order in which the catalog lists the components; verify it against the lot's certificate of analysis.

How is KLOW different from Glow? Glow is the three-component version — GHK-Cu, BPC-157 and TB-500. KLOW adds KPV as a fourth component and redistributes the mass. Functionally, KLOW is a repair stack with an inflammation-signalling component attached.

Why is BPC-157 the majority of the mass? The catalog does not explain the choice, and we will not invent a reason. What can be said is that BPC-157 is the largest of the four molecules and carries the broadest preclinical literature, and that a milligram figure is not a molar figure — 10 mg of a tripeptide contains far more molecules than 10 mg of a pentadecapeptide.

Has the combination itself been tested? No. The four components have been studied individually, mostly in cultured cells and rodent models. No peer-reviewed study has examined them together as a single mixture.

Is KLOW approved for human use? No. KLOW and its components are not approved drugs and not dietary supplements. All Patriot Labs products are sold strictly for in-vitro research and laboratory use only, and are not for human or veterinary consumption.

All Patriot Labs products are sold strictly for in-vitro research and laboratory use only. Not for human or veterinary consumption. This guide is educational and describes peptide chemistry and published research in general terms; it is not medical advice, does not describe how to use any product, and the references cited do not constitute a product claim.